News & Events

    • Latest News
  • What Drives Us
  • Leadership
    • Our Team
    • Board of Directors
    • Scientific Advisory Board
  • Science
    • The Science of Chronokines
    • Proteomic Discovery: Chronokines
    • Our Focus: Critical Diseases of Aging
  • Pipeline
    • Clinical Progress
    • AKST4290: Targeting Eotaxin
    • GRF6019 & GRF6021: Selected Plasma Fractions
    • AKST1210: Targeting Beta-2 Microglobulin
    • Clinical Trials
  • News & Events
    • Latest News
    • Publications & Presentations
  • Careers & Culture
    • Life at Alkahest
    • Benefits of Joining the Alkahest Family
    • Join Our Team in Making a Difference
  • Partners & Partnering
    • Current Partnerships
    • Partnering with Alkahest
  • Contact

Grifols to Make a Major Equity Investment in Alkahest

« Back to News

View Press Release (Grifols)

© 2024 Alkahest, Inc. All rights reserved. All images property of their respective owners. Cookies Policy | Privacy Policy | Cookies Settings.
Therapies Born from the Science of Plasma®
Alkhest Logo
MENU
  • What Drives Us
  • Leadership
    • Our Team
    • Board of Directors
    • Scientific Advisory Board
  • Science
    • The Science of Chronokines
    • Proteomic Discovery: Chronokines
    • Our Focus: Critical Diseases of Aging
  • Pipeline
    • Clinical Progress
    • AKST4290: Targeting Eotaxin
    • GRF6019 & GRF6021: Selected Plasma Fractions
    • AKST1210: Targeting Beta-2 Microglobulin
    • Clinical Trials
  • News & Events
    • Latest News
    • Publications & Presentations
  • Careers & Culture
    • Life at Alkahest
    • Benefits of Joining the Alkahest Family
    • Join Our Team in Making a Difference
  • Partners & Partnering
    • Current Partnerships
    • Partnering with Alkahest
  • Contact